Novavax Scores Another Nod For Its COVID-19 Shot In Adolescents

The Medicines and Healthcare products Regulatory Agency in the U.K. has granted expanded conditional approval for Novavax Inc's NVAX COVID-19 vaccine, Nuvaxovid (NVX-CoV2373), in adolescents aged 12 through 17.
The approval follows the FDA nod earlier this week.
"As we start to prepare for a potential fall surge, we are pleased to offer the first protein-based COVID-19 vaccine to adolescents aged 12 through 17 in the U.K.," said Stanley C. Erck, President, and CEO, of Novavax.
The expanded approval was based on data from the ongoing pediatric expansion of the Phase 3 PREVENT-19 trial of 2,247 adolescents.
Related: Novavax's Covid-19 Vaccine Cleared For Use In New Zealanders Aged 12-17.
Nuvaxovid achieved its primary endpoint in pediatric expansion and demonstrated 80% overall clinical efficacy when the Delta variant was predominant.
Also Read: Novavax Seeks FDA Emergency Use Nod For Its COVID-19 Vaccine Booster.
Preliminary safety data from the pediatric expansion showed the vaccine to be generally well-tolerated.
The U.K. approved the vaccine for adults as a two-dose regime in February.
Price Action: NVAX shares are down 4.48% at $35.58 on the last check Friday.
Photo by hakan german from Pixabay

Momentum51.59

Growth-

Quality-

Value28.27

Short

Medium

Long